Category Archives: Genetics

Genetics

Fulgent Genetics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference – Yahoo Finance

TEMPLE CITY, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics or the company), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020. These representatives of the company will host a presentation beginning at 1:00 p.m. ET.

A live webcast of the presentation will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. A replay of the webcast will be accessible on the Events section of the IR website beginning approximately one hour following the completion of the event.

About Fulgent Genetics

Fulgent Genetics proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (NGS) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Companys advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19), including NGS and reverse transcription polymerase chain reaction (RT-PCR) - based tests. The Company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Companys business is its ability to provide expansive options and flexibility for all clients unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

About Picture Genetics

Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from the ease and comfort of home, at an affordable price point. The Picture Genetics platform provides a holistic approach to at-home genetic screening by including oversight from independent physicians as well as genetic counseling options to complement Fulgent Genetics comprehensive genetic testing analysis. The Picture Genetics platform currently offers multiple tests, providing medically actionable, clinical-level results with professional medical follow-up in one easy process. Visit http://www.picturegenetics.com for more information.

Investor Relations Contact:The Blueshirt GroupMelanie Solomon, 415-217-4964, melanie@blueshirtgroup.com

Read the rest here:
Fulgent Genetics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference - Yahoo Finance

Genetics

BDRF, Baramati institute to identify genetic traits of landrace varieties of crops – The Indian Express

Written by Parthasarathi Biswas | Pune | September 3, 2020 11:14:01 pmTo encourage farmers, the programme marketed the produce under the brand, Farming Monk, in urban areas for a premium. (Representational)

SIX YEARS after they took up the work of conserving local or traditional (better known as landrace) varieties of rice, sorghum and vegetables, Pune-headquartered BAIF Development and Research Foundation (BDRF) now has plans to take their work to a molecular level. Along with National Institute for Abiotic Stress Management in Baramati, BDRF will try to identify genetic traits that allow these varieties to develop better climate resilience than more commonly grown commercial varieties.

Since January 2014, BDRF has started Maharashtra Gene Bank Programme for Conservation, Management and Revival of Local Resources.

Under the sponsorship of Rajiv Gandhi Science & Technology Commission of the state government, this project has been involved in preserving landrace varieties of crops like rice, millet, sorghum, maize, hyacinth bean, cowpea as well as indigenous livestock varieties for the past six years.

Vitthal Kauthale, thematic programme executive, BDRF, said the project saw both in situ (on spot) and ex situ conservation of landrace varieties. The project, which is to end by September 30, has so far seen conservation of 350 varieties of different crops in 25 in situ conservation at six clusters.

Kauthale said landraces, at present, are under threat with farmers opting for more commonly available commercial varieties. In fact, some of the rice varieties that the programme managed to salvage from near extinction, were now found only in tribal regions of Maharashtra, he said.

He also said these land varieties had better climate resilience than commercial varieties and could withstand heavy rainfall and other extreme climatic events.

During the last six years of the project, BDRF partnered with the local community for preserving local varieties. The process involves purification, trait identification, and then propagation of the variety at the farmer level. Last year, the project recorded production of 13.2 tonnes of worthy landraces of six focused races and availability of quality seeds through village-level community seed banks at six clusters and one central seed bank.

The project has involved self-help groups conserve and propagate crops. To encourage farmers, the programme marketed the produce under the brand, Farming Monk, in urban areas for a premium.

As the project comes to an end, BDRF has plans to upscale the project in a more scientific manner. To date, we were protecting and preserving landraces on field. Now, we wish to go to the molecular level and try to identify genetics that provide resilience to these varieties, Kauthale said.

He added that the collaboration with the Baramati institute aimed at doing the same, and once this was identified, the genes could be used to impart the same characteristic to commercial crops.

One of the major problems faced in conservation of landraces is the lack of any legal identity. The Seed Act, which governs the business of seeds, does not mention landraces and, thus, such seeds cannot be sold commercially. The BDRF has plans to take up policy-level intervention to allow the seeds to be traded.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Pune News, download Indian Express App.

The Indian Express (P) Ltd

Continue reading here:
BDRF, Baramati institute to identify genetic traits of landrace varieties of crops - The Indian Express

Genetics

Genus plc to Announce Preliminary 2020 Year End Financial and Business Results on September 8, 2020 – Business Wire

BASINGSTOKE, United Kingdom & MADISON, Wis.--(BUSINESS WIRE)--Genus plc (LSE: GNS), a world leading animal genetics company producing superior breeding livestock through genetic improvement, today announced that it will release its preliminary financial results for the full year ended June 30, 2020, and provide a business update on recent corporate developments in its worldwide porcine and bovine genetics businesses, on Tuesday, September 8, 2020.

Webcast Results PresentationA pre-recorded briefing by management to discuss the preliminary results for the year ended June 30, 2020 will be held via a video webcast facility and will be accessible at the following link beginning at 7:01 AM BST, 1:01 AM EDT on September 8th: https://webcasting.buchanan.uk.com/broadcast/5f28011c65023062edd7e24a.

An archived recording of the webcast will also be available on the Investors section of the Companys website.

About GenusGenus advances animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over 75 countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency and quality, and our customers use them to supply the global dairy and meat supply chains.

Genuss competitive edge comes from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

Headquartered in Basingstoke, United Kingdom, Genus companies operate in over 25 countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Go here to read the rest:
Genus plc to Announce Preliminary 2020 Year End Financial and Business Results on September 8, 2020 - Business Wire

Genetics

Fulgent Genetics, New York City Health and Hospitals Partner on Large-Scale Back-to-School COVID-19 Testing – GlobeNewswire

TEMPLE CITY, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (Nasdaq: FLGT) and New York City Health and Hospitals have announced they will provide COVID-19 testing to hundreds of thousands of students across approximately 1600 locations as they return to school in September and over the next several months. Fulgent will provide its FDA EUA-approved at-home test, Picture by Fulgent, a RT-PCR test that provides the highest level of sensitivity and specificity, utilizing a self-collected nasal swab sample. Fulgent will provide results within 24-48 hours from the time when Fulgent receives and accepts a specimen for the test.

Fulgent is very happy to partner with the City of New York on such an important and novel testing protocol. Its an ambitious goal to test so many students in such a rapid fashion, but the combination of the Fulgent technology platform and lab capacity along with the strong testing infrastructure of New York City makes this possible, commented Brandon Perthuis, Chief Commercial Officer of Fulgent Genetics. In just a few short days, we were able to get the first shipment of hundreds of thousands of Picture kits to New York City. We will now be working closely with the city on the distribution, return and replenishment of the kits, added Perthuis.

This is one of the first large-scale testing programs for COVID-19 to utilize an at-home test kit. Fulgents Picture Genetics at-home test was chosen due to its convenient self-administration, which can be used on-site at schools as well as at home. The companys industry-leading turnaround time of 24-48 hours also makes this a powerful tool for back-to-school testing.

About NYC Test & Trace Corps

The NYC Test & Trace Corps is a public health initiative to fight COVID-19 so that New Yorkers can get back to school, work and help New York City reopen safely. The Corps is a group of doctors, public health professionals and community advocates working to reverse the COVID-19 outbreak and protect our city. The public health program is led by NYC Health + Hospitals in close collaboration with the NYC Department of Health and Mental Hygiene and other city agencies. Through its robust and citywide partnerships, The Corps helps New Yorkers receive free, safe and confidential testing for COVID-19 and for the antibody test. It ensures that anyone with the virus receives care and can safely isolate to prevent the spread. For more information, visit https://www.nychealthandhospitals.org/test-and-trace/.

About Fulgent Genetics

Fulgent Genetics proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (NGS) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Companys advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19), including NGS and reverse transcription polymerase chain reaction (RT-PCR) - based tests. The Company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Companys business is its ability to provide expansive options and flexibility for all clients unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

About Picture Genetics

Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from the ease and comfort of home, at an affordable price point. The Picture Genetics platform provides a holistic approach to at-home genetic screening by including oversight from independent physicians as well as genetic counseling options to complement Fulgent Genetics comprehensive genetic testing analysis. The Picture Genetics platform currently offers multiple tests, providing medically actionable, clinical-level results with professional medical follow-up in one easy process. Visit http://www.picturegenetics.comfor more information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: the companys identification and evaluation of opportunities and its ability to capitalize on opportunities to grow its business; expected future lab capacity and turnaround times; expectations or guidance regarding future revenues and managements judgements and evaluations of the companys platform and technology.

Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the companys future performance, and they are based on managements current assumptions, expectations and beliefs concerning future developments and their potential effect on the companys business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for its tests and the pandemics effects on the global supply chain; the market potential for, and the rate and degree of market adoption of, the companys tests, including its newly-developed tests for COVID-19 and genetic testing generally; the companys ability to capture a sizable share of the developing market for genetic and COVID-19 testing and to compete successfully in these markets, including its ability to continue to develop new tests that are attractive to its various customer markets, its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the companys ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the companys ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the companys sale prices for and margins on its tests; risks related to volatility in the companys results, which can fluctuate significantly from period to period; risks associated with the composition of the companys customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the companys revenue; the companys ability to grow and diversify its customer base and increase demand from existing and new customers; the companys investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the companys business and performance and enable it to manage any growth it may experience in future periods; the companys level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the companys level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the companys compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the companys international operations; the companys ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.

The forward-looking statements made in this press release speak only as of the date of this press release, and the company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law.

The companys reports filed with the U.S. Securities and Exchange Commission (SEC), including its annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 13, 2020 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the companys website upon their filing with the SEC. These reports contain more information about the company, its business and the risks affecting its business.

Investor Relations Contact:The Blueshirt GroupMelanie Solomon, 415-217-4964, melanie@blueshirtgroup.com

Media Contact:The Blueshirt GroupJeff Fox, 415-828-8298, jeff@blueshirtgroup.com

Excerpt from:
Fulgent Genetics, New York City Health and Hospitals Partner on Large-Scale Back-to-School COVID-19 Testing - GlobeNewswire

Genetics

Introducing Seattle Genetics (NASDAQ:SGEN), The Stock That Zoomed 272% In The Last Five Years – Yahoo Finance

When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really flourishing, you can make more than 100%. Long term Seattle Genetics, Inc. (NASDAQ:SGEN) shareholders would be well aware of this, since the stock is up 272% in five years. Then again, the 9.1% share price decline hasn't been so fun for shareholders.

See our latest analysis for Seattle Genetics

Given that Seattle Genetics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

For the last half decade, Seattle Genetics can boast revenue growth at a rate of 24% per year. Even measured against other revenue-focussed companies, that's a good result. Meanwhile, its share price performance certainly reflects the strong growth, given the share price grew at 30% per year, compound, during the period. So it seems likely that buyers have paid attention to the strong revenue growth. To our minds that makes Seattle Genetics worth investigating - it may have its best days ahead.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth

Seattle Genetics is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus forecasts

We're pleased to report that Seattle Genetics shareholders have received a total shareholder return of 115% over one year. That's better than the annualised return of 30% over half a decade, implying that the company is doing better recently. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 1 warning sign we've spotted with Seattle Genetics .

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

See the original post:
Introducing Seattle Genetics (NASDAQ:SGEN), The Stock That Zoomed 272% In The Last Five Years - Yahoo Finance

Genetics

Diabetes risk impacted more by excess weight than genetics, experts say – Clinical Daily News – McKnight’s Long Term Care News

Excess body weight is a much more powerful risk factor for developing type 2 diabetes than genetics, according to a new study. Bringing weight below an individualized trigger threshold could prevent or even reverse the disease, investigators say.

Data from more than 440,000 adult participants in the UK Biobank study was grouped according to genetic risk of diabetes, and body mass index (a measurement of weight adjusted to height). The group with the highest BMI had 11 times the risk of diabetes compared with participants in the lowest BMI group. The highest BMI group also had a greater likelihood of developing diabetes than all other BMI groups, regardless of genetic risk.

In addition, being overweight for a longer period of time had no effect on risk, the researchers found. This result suggests that when a certain BMI threshold is crossed, the odds of developing diabetes increase and remain high no matter how long an individual is overweight, said Brian Ference, M.D., an epidemiologist from the University of Cambridge, England, and University of Milan, Italy.

The findings indicate that most cases of diabetes could be avoided by keeping BMI below the cut-off which triggers abnormal blood sugar, Ference said. This means that to prevent diabetes, both BMI and blood sugar should be assessed regularly. Efforts to lose weight are critical when a person starts to develop blood sugar problems, he concluded.

The study was presented Monday at the European Society of Cardiology Congress 2020.

Read this article:
Diabetes risk impacted more by excess weight than genetics, experts say - Clinical Daily News - McKnight's Long Term Care News

Genetics

Long-Lasting Wound Infections Linked to Microbes and Genetics – The Scientist

The paper

C. Tipton et al., Patient genetics is linked to chronic wound microbiome composition and healing, PLOS Pathog, 16:e1008511, 2020.

How quickly scrapes, cuts, and gashes in the skin heal can vary greatly depending on a persons body mass, age, and whether the individual suffers from certain chronic conditions such as diabetes. Genetics, a new study suggests, may also play a role, with variations in two specific genes lowering the diversity of a wounds microbiome and lengthening healing time.

Through a partnership with Southwest Regional Wound Care Center in Lubbock, Texas, geneticist Caleb Phillips at Texas Tech University and colleagues gained access to 85 patients DNA samples. Analyzing each persons sample and comparing it to the diversity of bacteria in the patients infected wound, the team found that individuals with specific single nucleotide polymorphisms (SNPs) in TLN2, a gene involved in actin assembly, and ZNF521, which encodes a transcription factor, had lower overall microbial diversity in their wounds and were much more likely to suffer from Pseudomonas and Staphylococcus infections. Those patients skin injuries were also much slower to heal, suggesting that individuals with these specific TLN2 and ZNF521 mutations may be at higher risk of developing chronic wounds.

Despite the modest sample size, Phillips says, the study offers a better understanding of what makes a patient vulnerable to chronic wounds. The SNPs the team described in TLN2 and ZNF521 could serve as biomarkers to identify patients at risk for slow wound recovery, he notes.

The extent of the microbiomes role in chronic wounds is a really big question in the field of healing and repair, notes Lindsay Kalan, a medical microbiologist and immunologist at the University of WisconsinMadison who was not involved in the study. While the papers results are not immediately translatable for patient care, she says, it is definitely a step in the right direction.

Continue reading here:
Long-Lasting Wound Infections Linked to Microbes and Genetics - The Scientist

Genetics

Genetic Testing Services Market: Surge in Adoption of Genetic Testing Services to Boost the Market – BioSpace

Transparency Market Research (TMR) has published a new report titled, Genetic Testing Services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027.According to the report, the global Genetic Testing Services market was valued at US$ 41.2 Bn in 2018 and is projected to expand at a CAGR of 7.3% from 2019 to 2027.

Overview

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10235

New Born Screening Segment to Dominate Global Genetic Testing Services Market

Request for Analysis of COVID19 Impact on Genetic Testing Services Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=10235

Oncology Segment Hold a Major Share of Global Genetic Testing Services Market

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=10235

Hospitals based laboratories Segment to Dominate Global Genetic Testing Services Market

North America to Dominate Global Genetic Testing Services Market

Buy Genetic Testing Services Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=10235&ltype=S

Competitive Landscape

The global genetic testing services market is consolidated in terms of number of players. Key players in the global Genetic Testing Services market include Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Genomic Health, Inc., NeoGenomics Laboratories, Inc, Eurofins Scientific, Ambry Genetics, Illumina, Inc, 23andMe, Inc., Exact Sciences, Natera, Invitae, Veracyte, and other prominent players.

Browse More Trending Reports by Transparency Market Research:

Nitinol Stents Market: https://www.transparencymarketresearch.com/nitinol-stents-market.html

Neurology Sterile Injectable Market: https://www.transparencymarketresearch.com/neurology-sterile-injectable-market.html

Microplate Systems Market: https://www.transparencymarketresearch.com/microplate-systems-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read this article:
Genetic Testing Services Market: Surge in Adoption of Genetic Testing Services to Boost the Market - BioSpace

Genetics

PREDICTIVE GENETIC TESTING AND CONSUMER/WELLNESS GENOMICS MARKET TRENDS AND DYNAMIC 2025 – Scientect

Predictive Genetic Testing and Consumer/Wellness Genomics Market: Snapshot

Genetic testing comprises examination of ones DNA. The term DNA refers to the chemical database that is responsible for conveying the instructions for functions that need to be performed by the body. Genetic testing is capable of revealing changes or mutations in the genes of living beings, which might result in any kind of disease or illness in the body.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1274

Predictive genetic testingrefers to the utilization of genetic testing methods in an asymptomatic individual to make a prediction about risk of contacting particular disease in future. These tests are regarded as representation of emerging class of medical tests, which differ in fundamental ways from the usual diagnostic tests.

The global predictive genetic testing and consumer/wellness genomics marketis likely to gather momentum owing to the benefits offered by predictive genetic testing.

The benefits of predictive genetic testing are

The global predictive genetic testing and consumer/wellness genomics marketis influenced by reducing cost of genetic sequencing and technological advancement in the field of genetics. North America is expected to emerge as a prominent region for the global predictive genetic testing and consumer/wellness genomics market in years to come due to high adoption rates of latest technologies in all fields.

Over centauries human DNA has undergone tremendous alteration due to evolutionary and lifestyle changes. They have led to both, advantages and disadvantages over the years. Some have given the mankind a deserving edge over other creatures while the others have led to disorders and diseases. Predictive genetic testing and consumer/wellness genomics market thrives on the growing demand for understanding the lineage of a certain gene pool to identify disorders that could manifest in the later or early stage of a human life. The surging demand for understanding the family history or studying the nature of certain diseases has given the global market for predictive genetic testing and consumer/wellness genomics market adequate fodder for growth in the past few years.

This new class of medical tests are aimed at reducing the risk of morbidity and mortality amongst consumers. The thorough surveillance and screening of a certain gene pool can allow an individual to avoid conditions that disrupt normal existence through preventive measures. The clinical utility of these tests remains unassessed. Therefore, increasing research and development by pharmaceutical companies to develop new drugs by understanding diseases and disorders is expected to favor market growth.

Unlike conventional diagnostic testing, predictive genetic testing identifies the risk associated with potential conditions. In certain cases it is also capable of stating when the disease may appear and the how severe will it be. Thus, this form of testing is expected to allow consumers to take up wellness measurements well in time to lead a life of normalcy, characterized by good health.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1274<ype=S

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Overview

Predictive genetic testing are used to identify gene mutations pertaining to the disorders that surface at a considerably later stage in life after birth. These tests are particularly beneficial for people from a family with a history of genetic disorder, although they themselves show no symptoms of the disorder at the time of testing. Genetic testing promises to revolutionize the healthcare sector, providing crucial diagnostic details related to diverse verticals such as heart disease, autism, and cancer. As the healthcare sector touches new peaks, the global predictive genetic testing and consumer/wellness genomics market is projected to expand at a healthy growth rate during the forecast period of 2017 to 2025.

This report on the global market for predictive genetic testing and consumer/wellness genomics analyzes all the important factors that may influence the demand in the near future and forecasts the condition of the market until 2025. It has been created using proven research methodologies such as SWOT analysis and Porters five forces. One of the key aspect of the report is the section on company profiles, wherein several leading players have been estimated for their market share and analyzed for their geographical presence, product portfolio, and recent strategic developments such as mergers, acquisitions, and collaborations.

The global predictive genetic testing and consumer/wellness genomics market, on the basis of test type, can be segmented into predictive testing, consumer genomics, and wellness genetics. The segment of predictive testing can be sub-segmented into genetic susceptibility test, predictive diagnostics, and population screening programs, whereas the segment of wellness genetics can be further divided into nutria genetics, skin and metabolism genetics, and others.

By application, the market can be segmented into breast and ovarian cancer screening, cardiovascular screening, diabetic screening and monitoring, colon cancer screening, Parkinsons or Alzheimers disease, urologic screening or prostate cancer screening, orthopedic and musculoskeletal screening, and other cancer screening. Geographically, the report studies the opportunities available in regions such as Asia Pacific, Europe, North America, and the Middle East and Africa.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Trends and Opportunities

Increasing number of novel partnership models, rapidly decreasing cost of genetic sequencing, and introduction of fragmented point-solutions across the genomics value chain as well as technological advancements in cloud computing and data integration are some of the key factors driving the market. On the other hand, the absence of well-defined regulatory framework, low adoption rate, and ethical concerns regarding the implementation, are expected to hinder the growth rate during the forecast period. Each of these factors have been analyzed in the report and their respective impacts have been anticipated.

Currently, the segment of predictive genetic cardiovascular screening accounts for the maximum demand, and increased investments in the field is expected to maintain it as most lucrative segment. On the other hand, more than 70 companies are currently engaged in nutrigenomics, which is expected to further expand the market.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Regional Outlook

Owing to robust healthcare infrastructure, prevalence of cardiovascular diseases, and high adoptability rate of new technology makes North America the most lucrative region, with most of the demand coming from the country of the U.S. and Canada. Several U.S. companies hold patents, which further extends the outreach of the market in the region of North America.

Companies mentioned in the research report

23andMe, Inc, BGI, Genesis Genetics, Illumina, Inc, Myriad Genetics, Inc, Pathway Genomics, Color Genomics Inc., and ARUP Laboratories are some of the key companies currently operating in global predictive genetic testing and consumer/wellness genomics market. Various forms of strategic partnerships with operating company and smaller vendors with novel ideas helps these leading players maintain their position in the market.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1274

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read more from the original source:
PREDICTIVE GENETIC TESTING AND CONSUMER/WELLNESS GENOMICS MARKET TRENDS AND DYNAMIC 2025 - Scientect

Genetics

Three Have Tested Positive: Second Testing ‘Imperative’ – Iceland Monitor

Kri Stefnsson, CEO of deCode Genetics. mbl.is/Kristinn Magnsson

Since August 19 , when Iceland began testing all arriving passengers twice for the coronavirus at the border - first upon arrival and then four to five days later - three people have tested positive during the second test, Kri Stefnsson, CEO of deCode Genetics, tells mbl.is .

This is three times as much as we expected, he states. Before these rules were implemented for all arriving passengers, 8,000 Icelanders or residents of Iceland had been subjected to the double screening rule. Among them, we found two who tested positive [the second time], albeit with a large amount of the virus and, therefore, very contagious, Kri explains. Either one of them could have set off a new wave of this pandemic.

The limited experience we have from the second screening suggests it is imperative, he adds. Of course, the experience is very limited, but we must look at this in light of the fact that this virus is setting off a new wave in the countries around us. Its nonsense to assert that it is disappearing and that there is nothing to fear.

Some people have criticized the new rules at the border, calling them too strict, Jn var Einarsson, MD, an Icelandic professor at Harvard Medical School, among them. He believes the rules limit peoples freedom too much and fears that too strict rules may lead to people no longer respecting them.

Kri, on the other hand, states that the rules at the border reduce the likelihood of having to impose strict rules domestically, since the chance of new infections being spread to the country are reduced.

It is important, he states, to focus on what we gain, not just what we lose, through implementing this system. Among the things we gain is that we can operate our schools as usual. There is nothing as important for society than taking good care of children and youth in our schools. The system [of double testing at the border] makes it possible for disease prevention measures not to threaten other industries in the country.

In the long run, he states, it is in the long-term interest of the travel industry to be able to say that we are a nation that takes good care of its people, and people can come here because we are safe here.

According to covid.is , no new domestic case of COVID-19 was confirmed in Iceland yesterday, while two people who tested positive at the border still await the results of an antibody test. At present, there are 100 active cases of the disease in Iceland, and 900 people are in quarantine. The 14-day incidence per 100,000 inhabitants now stands at 24.9, which is lower than it has been in recent days.

Excerpt from:
Three Have Tested Positive: Second Testing 'Imperative' - Iceland Monitor